https://contin-u.com/news/ Plain-language summaries of peptides, FDA regulation, and TRT studies from Contin-U Medical. Educational only — not medical advice. en-us Mon, 10 Aug 2026 00:00:00 -0400 https://contin-u.com/news/2026-08-10-eau-2026-hypogonadism-guidelines-shbg-free-t The European Association of Urology's 2026 Sexual and Reproductive Health Guidelines update (published August 10, 2026) formalizes broader use of SHBG and calculated free testosterone, preserves the 12 nmol/L total testosterone threshold, and significantly revises Section 3.5.4 on TRT in men with prostate cancer history. Mon, 10 Aug 2026 00:00:00 -0400 https://contin-u.com/news/2026-08-10-eau-2026-hypogonadism-guidelines-shbg-free-t https://contin-u.com/news/2026-08-03-fda-trt-label-overhaul-2026 On June 18, 2026, HHS and the FDA formally requested class-wide testosterone-therapy label updates that would remove the age-related hypogonadism limitation, narrow the prostate cancer contraindication to metastatic disease only, and revise the BPH warning. Here's what has actually changed, what hasn't, and how Contin-U practices today. Mon, 03 Aug 2026 00:00:00 -0400 https://contin-u.com/news/2026-08-03-fda-trt-label-overhaul-2026 https://contin-u.com/news/2026-07-21-traverse-trial-one-year-later-trt-cardiovascular-safety The 2023 TRAVERSE trial (NEJM) put decades of TRT cardiovascular safety questions to rest — but only if you read what it actually said. Here's what the 5,246-patient RCT concluded, what caveats remain, and how it changed real prescribing. Tue, 21 Jul 2026 00:00:00 -0400 https://contin-u.com/news/2026-07-21-traverse-trial-one-year-later-trt-cardiovascular-safety